Mycobacterium tuberculosis (Mtb) is one of the most important infectious agents worldwide
and causes more than 1.5 million deaths annually. To make matters worse, the drug …

While the global market for peptide/protein-based therapeutics is witnessing significant
growth, the development of peptide drugs remains challenging due to their low oral …

Drug-resistant tuberculosis (TB) has lent urgency to finding new drug leads with novel
modes of action. A high-throughput screening campaign of> 65,000 actinomycete extracts …

Tuberculosis (TB) continues to be a significant cause of mortality and morbidity worldwide.
An estimated 2 billion individuals are infected with Mycobacterium tuberculosis and annually …

The rise of multi-and extensively drug-resistant Mycobacterium tuberculosis (M. tb) strains
and co-infection with human immunodeficiency virus has escalated the need for new anti-M …

Covering: up to 2017 The bacterial Clp protease is a highly conserved and structurally
versatile machine. It has gained a lot of recognition during the last decade as a novel …

The Clp protease complex in Mycobacterium tuberculosis is unusual in its composition,
functional importance and activation mechanism. Whilst most bacterial species contain a …

In the post-antibiotic era, the rapid development of antibiotic resistance and the shortage of
available antibiotics are triggering a new health-care crisis. The discovery of novel and …

Addressing the urgent need to develop novel drugs against drug-resistant Mycobacterium
tuberculosis (M. tb) strains, ecumicin (ECU) and rufomycin I (RUFI) are being explored as …

A new nonribosomal peptide, nyuzenamide C (1), was discovered from riverine sediment-
derived Streptomyces sp. DM14. Comprehensive analysis of the spectroscopic data of …